Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. This paper aims at filling the information gap, assessing the cost of implementing CAR-T activity and the full cost of managing the CAR-T clinical pathway.
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Cavallo, Maria Caterina;Cavazza, Marianna;Jommi, Claudio
2024
Abstract
Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. This paper aims at filling the information gap, assessing the cost of implementing CAR-T activity and the full cost of managing the CAR-T clinical pathway.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
BMC_HealthServiceRes_2024_Cavallo_etal_CAR_T.pdf
accesso aperto
Descrizione: article
Tipologia:
Pdf editoriale (Publisher's layout)
Licenza:
Creative commons
Dimensione
1.37 MB
Formato
Adobe PDF
|
1.37 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
